|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|||
| 化学式 | C15H14O3S2 |
||||||
| 分子量 | 306.40 | CAS No. | 292605-14-2 | ||||
| Solubility (25°C)* | 体外 | DMSO | 61 mg/mL (199.08 mM) | ||||
| Ethanol (warmed with 50ºC water bath) | 10 mg/mL (32.63 mM) | ||||||
| Water | Insoluble | ||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||
| 製品説明 | SB-3CT is an effective and selective gelatinase inhibitor with Ki of 13.9 nM and 600 nM for MMP-2 and MMP-9, respectively. |
|---|---|
| in vitro | SB-3CT directly inhibits bone marrow endothelial cell invasion and tubule formation in Matrigel in vitro. [3] |
| in vivo | In L-CI.5s T-cell lymphoma model, SB-3CT (5-50 mg/kg/d i.p.) potently inhibit liver metastasis and increases survival of mice. [2] This compound (50 mg/kg/d i.p.) inhibits human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model. [3] In a mouse model of embolus-induced “permanent” focal cerebral ischemia, this chemical counteracts degradation of neuronal laminin, protects neurons from ischemic cell death, and ameliorates neurobehavioral outcomes after embolic MCA occlusion. [4] |
| キナーゼアッセイ | Fluorescence enzymatic activity assays | |
|---|---|---|
| The enzymatic activity of MMP-2, MMP-9 and MMP-7 is monitored with the fluorescence quenched substrate MOCAcPLGLA2pr(Dnp)-AR-NH2. Fluorescence is measure with a PTI spectrofluorometer. The cuvette compartment is thermostated at 25 ℃ 。 | ||
| 細胞アッセイ | 細胞株 | HCC cells |
| 濃度 | 0.1 μM | |
| 反応時間 | 24 h | |
| 実験の流れ | Cells were treated with indicated concentration of SB-3CT for 24 h. | |
| 動物実験 | 動物モデル | Mouse L-CI.5s T-cell lymphoma model |
| 投薬量 | 50 mg/kg/d | |
| 投与方法 | i.p. | |
|

Data from [Data independently produced by , , Cell Physiol Biochem, 2017, 44(6):2281-2295]

Data from [Data independently produced by , , Mol Nutr Food Res, 2018, doi:10.1002/mnfr.201700969]

Data from [Data independently produced by , , Neuropharmacology, 2017, 118:157-166]
| High matrix metalloproteinase-2 expression predicts poor prognosis of colon adenocarcinoma and is associated with PD-L1 expression and lymphocyte infiltration [ PeerJ, 2025, 13:e19550] | PubMed: 40611940 |
| An MMP-9 exclusive neutralizing antibody attenuates blood-brain barrier breakdown in mice with stroke and reduces stroke patient-derived MMP-9 activity [ Pharmacol Res, 2023, 190:106720] | PubMed: 36893823 |
| COL4A3 Mutation Induced Podocyte Apoptosis by Dysregulation of NADPH Oxidase 4 and MMP-2 [ Kidney Int Rep, 2023, 8(9):1864-1874] | PubMed: 37705901 |
| Inhibition of MMP-2 and MMP-9 attenuates surgery-induced cognitive impairment in aged mice [ Brain Res Bull, 2023, 204:110810] | PubMed: 37939860 |
| Microglial Activation Damages Dopaminergic Neurons through MMP-2/-9-Mediated Increase of Blood-Brain Barrier Permeability in a Parkinson's Disease Mouse Model [ Int J Mol Sci, 2022, 23(5)2793] | PubMed: 35269933 |
| MMP2 and MMP9 Activity Is Crucial for Adult Visual Cortex Plasticity in Healthy and Stroke-Affected Mice [ J Neurosci, 2022, 42(1):16-32] | PubMed: 34764155 |
| Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies [ Cancers (Basel), 2022, 14(7)1630] | PubMed: 35406401 |
| MMP2 and MMP9 contribute to lung ischemia-reperfusion injury via promoting pyroptosis in mice [ BMC Pulm Med, 2022, 22(1):230] | PubMed: 35705936 |
| Rotenone impairs learning and memory in mice through microglia-mediated blood brain barrier disruption and neuronal apoptosis [ Chemosphere, 2021, S0045-6535(21)03454-8] | PubMed: 34822863 |
| GSK-3α/β Activity Negatively Regulates MMP-1/9 Expression to Suppress Mycobacterium tuberculosis Infection [ Front Immunol, 2021, 12:752466] | PubMed: 35095838 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。